AAD 2026Abstract 75116
A pooled analysis of the hemostatic safety profile of remibrutinib over 24 weeks in patients with chronic spontaneous urticaria from the REMIX-1 and REMIX-2 phase 3 studies
Lebwohl M, Saini S, Hide M, Berard F, Li L, Incera E, Zouater H, Lheritier K, Zharkov A, Brockow K
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: Urticaria
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.099 · Not in PubMed: details from Crossref